
Human Pumilio homolog 3 289-297, RTLDKVLEV
Description
About Human Pumilio homolog 3 289-297, RTLDKVLEV
The Human Pumilio homolog 3 Peptide (IEDB: 141408) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Pumilio homolog 3 Peptide, H-RTLDKVLEV-OH (Uniprot: Q15397 aa: 289-297) from JPT is produced under strict quality control and quality management.
Human Pumilio homolog 3 289-297, RTLDKVLEV - Specifications
- Peptide sequence: H-RTLDKVLEV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Pumilio homolog 3 289-297, RTLDKVLEV
References:
Read References with JPT’s Antigen Peptides
Human Pumilio homolog 3 289-297, RTLDKVLEV has been described in:
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing., J Exp Med, 2001 (PMID: 11148223)
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation., Biol Blood Marrow Transplant, 2013 (PMID: 23022467)
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations., Cell Rep Methods, 2021 (PMID: 35474673)
Documentation
Documentation for Human Pumilio homolog 3 289-297, RTLDKVLEV
Properties
Properties of Human Pumilio homolog 3 289-297, RTLDKVLEV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Pumilio homolog 3 289-297, RTLDKVLEV
Information | Values |
---|---|
Sequence: | H-RTLDKVLEV-OH |
Specifications: | 9mer peptide as TFA salt |